Share Prices & Company Research

Market News

02 Mar 2021 | 15:42

EU considers emergency approvals for Covid-19 vaccines

(Sharecast News) - The European Commission said on Tuesday it was considering emergency approvals for Covid-19 vaccines.

The move would be an alternative to the more rigorous conditional marketing authorisations used so far. To date, emergency approvals have been considered dangerous as it could mean hasty use of treatments without the sufficient safety checks.

According to Reuters, this kind of procedure had been reserved for exceptional authorisations at the national level of drugs for terminally ill patients, including cancer treatments.

The potential change comes as the EU executive comes under pressure for what some consider slow vaccine approvals and rollouts.

"We are ready to reflect with the member states on all possible avenues to indeed accelerate the approval of the vaccines," an EU Commission spokesman told a news conference.

One option could be "an emergency authorisation of vaccines at EU level with shared liability among member states", the spokesman said.

The European Medicines Agency (EMA) cannot currently issue emergency approvals but in exceptional circumstances has recommended the compassionate use of drugs before marketing authorisation, said Reuters.

Regarding Covid, the EMA approved Gilead's antiviral drug remdesivir as a treatment against the illness. The drug was later given conditional approval by EMA.

Some Eastern European countries, including Hungary, Slovakia and the Czech Republic have already approved Russian and Chinese vaccines with national emergency procedures.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.